(NPR) – Norditropin, the growth hormone prescribed most often, went into shortage in the fall of 2022. It’s still scarce a year and a half later, despite assurances from Novo Nordisk, maker of the drug, that supplies would stabilize in 2024. As people try to switch to other brands, a ripple effect has been causing shortages of those products too. (Read More)